Showing results (1-10 of 37) with videos related to
Sort By:
Pageof 4
Neurodegenerative Disease Management|July 21, 2020
Diroximel fumarate in the treatment of multiple sclerosisElise Jonasson, Tobias SejbaekIdeggyogyaszati Szemle|July 18, 2015
[ALEMTUZUMAB: BENEFITS AND CHALLENGES OF A NEW THERAPY IN MULTIPLE SCLEROSIS]Zsolt Illés, Tobias Sejbaek, Tünde CsépányMultiple Sclerosis and Related Disorders|December 7, 2016
Practice effect in Symbol Digit Modalities Test in multiple sclerosis patients treated with natalizumabMalte Roar, Zsolt Illes, Tobias SejbaekDanish Medical Journal|July 5, 2022
Limited value of a patient-reported triage algorithm in an outpatient epilepsy clinicEva Myrdal, Tanja Viktoria Danielsen, Tobias SejbaekDanish Medical Journal|June 21, 2023
Comment: Reply to editorial letter on Limited value of a patient-reported triage algorithm in an outpatient epilepsy clinicEva Myrdal, Tatiana Viktoria Danielsen, Tobias SejbaekMultiple Sclerosis and Related Disorders|June 16, 2018
Real-life persistence and tolerability with dimethyl fumarateTobias Sejbaek, Mads Nybo, Thor Petersen, et al.Clinical Ophthalmology (Auckland, N.Z.)|September 2, 2017
Long-term structural retinal changes in patients with optic neuritis related to multiple sclerosisMaria Rene Andersen, Malte Roar, Tobias Sejbaek, et al.Journal of Neuroimmunology|April 2, 2022
Inflammatory profiles in plasma and cerebrospinal fluid of patients with neurosarcoidosisKeld-Erik Byg, Zsolt Illes, Tobias Sejbaek, et al.BMJ Neurology Open|March 8, 2021
Comparison of neurofilament light chain results between two independent facilitiesTobias Sejbaek, Jason P Mendoza, Natasha Penner, et al.Multiple Sclerosis and Related Disorders|August 9, 2022
Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosisJulie Ravn, Henrik Boye Jensen, Matthias Kant, et al.Pageof 4